Jefferies Thinks Alcobra’s Stock is Going to Recover

By Jason Carr

Jefferies analyst Biren Amin reiterated a Buy rating on Alcobra (NASDAQ: ADHD) today and set a price target of $6. The company’s shares closed yesterday at $1.85, close to its 52-week low of $1.77.

According to, Amin is a 5-star analyst with an average return of 6.9% and a 54.1% success rate. Amin covers the Healthcare sector, focusing on stocks such as Bellicum Pharmaceuticals, Anthera Pharmaceuticals, and Aquinox Pharmaceuticals.

Alcobra has an analyst consensus of Hold, with a price target consensus of $2.98.

Based on Alcobra’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $0 and GAAP net loss of $5.79 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $4.26 million.

Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel.